Previous reports suggest that polymorphisms in PD-1 and PD-L1 are associated with a higher risk of gastric, bladder, and hepatocellular cancers [8], irAEs [9], better survival outcomes in non-small cell lung cancer (NSCLC) [10] and prostate cancer [11], and extended clinical benefit in NSCLC [12]. Here, PDCD1 is linked to non-small cell lung carcinoma.